These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 36776236)

  • 21. Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit.
    Suleyman G; Fadel RA; Malette KM; Hammond C; Abdulla H; Entz A; Demertzis Z; Hanna Z; Failla A; Dagher C; Chaudhry Z; Vahia A; Abreu Lanfranco O; Ramesh M; Zervos MJ; Alangaden G; Miller J; Brar I
    JAMA Netw Open; 2020 Jun; 3(6):e2012270. PubMed ID: 32543702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity.
    Pasquarelli-do-Nascimento G; Braz-de-Melo HA; Faria SS; Santos IO; Kobinger GP; Magalhães KG
    Front Endocrinol (Lausanne); 2020; 11():530. PubMed ID: 32849309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Obesity With COVID-19 Severity and Mortality: An Updated Systemic Review, Meta-Analysis, and Meta-Regression.
    Singh R; Rathore SS; Khan H; Karale S; Chawla Y; Iqbal K; Bhurwal A; Tekin A; Jain N; Mehra I; Anand S; Reddy S; Sharma N; Sidhu GS; Panagopoulos A; Pattan V; Kashyap R; Bansal V
    Front Endocrinol (Lausanne); 2022; 13():780872. PubMed ID: 35721716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obesity pandemic during COVID-19 outbreak: Narrative review and future considerations.
    Cava E; Neri B; Carbonelli MG; Riso S; Carbone S
    Clin Nutr; 2021 Apr; 40(4):1637-1643. PubMed ID: 33765600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID 19 in-hospital mortality, body mass index and obesity related conditions.
    Sidhu G; Samson R; Nedunchezian SH; Srivastav S; Dixit N; Le Jemtel TH
    J Diabetes Complications; 2021 Dec; 35(12):108054. PubMed ID: 34600823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiopulmonary Pathophysiological Aspects in the Context of COVID-19 and Obesity.
    Fayssoil A; De Carnavalet MCC; Mansencal N; Lofaso F; Davido B
    SN Compr Clin Med; 2021; 3(9):1848-1857. PubMed ID: 34151188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics and outcomes of patients with COVID-19 admitted to hospital and intensive care in the first phase of the pandemic in Canada: a national cohort study.
    Murthy S; Archambault PM; Atique A; Carrier FM; Cheng MP; Codan C; Daneman N; Dechert W; Douglas S; Fiest KM; Fowler R; Goco G; Gu Y; Guerguerian AM; Hall R; Hsu JM; Joffe A; Jouvet P; Kelly L; Kho ME; Kruisselbrink RJ; Kumar D; Kutsogiannis DJ; Lamontagne F; Lee TC; Menon K; O'Grady H; O'Hearn K; Ovakim DH; Pharand SG; Pitre T; Reel R; Reeve B; Rewa O; Richardson D; Rishu A; Sandhu G; Sarfo-Mensah S; Shadowitz E; Sligl W; Solomon J; Stelfox HT; Swanson A; Tessier-Grenier H; Tsang JLY; Wood G;
    CMAJ Open; 2021; 9(1):E181-E188. PubMed ID: 33688026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Characteristics and Outcomes of COVID-19 Patients with Overweight and Obesity: Turkish Nationwide Cohort Study (TurCObesity).
    Sahin I; Haymana C; Demir T; Demirci I; Tasci I; Atmaca A; Cakal E; Ata N; Emral R; Unluturk U; Ertugrul D; Salman S; Sahin M; Dagdelen S; Celik O; Caglayan M; Satman I; Sonmez A
    Exp Clin Endocrinol Diabetes; 2022 Feb; 130(2):115-124. PubMed ID: 34384122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe Acute Respiratory Syndrome by SARS-CoV-2 Infection or Other Etiologic Agents Among Brazilian Indigenous Population: An Observational Study from the First Year of Coronavirus Disease (COVID)-19 Pandemic.
    Sansone NMS; Boschiero MN; Ortega MM; Ribeiro IA; Peixoto AO; Mendes RT; Marson FAL
    Lancet Reg Health Am; 2022 Apr; 8():100177. PubMed ID: 35018359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obesity-Related Inflammation and Endothelial Dysfunction in COVID-19: Impact on Disease Severity.
    De Lorenzo A; Estato V; Castro-Faria-Neto HC; Tibirica E
    J Inflamm Res; 2021; 14():2267-2276. PubMed ID: 34079332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between body-mass index, patient characteristics, and obesity-related comorbidities among COVID-19 patients: A prospective cohort study.
    Tong L; Khani M; Lu Q; Taylor B; Osinski K; Luo J
    Obes Res Clin Pract; 2023; 17(1):47-57. PubMed ID: 36577559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proper Management of People with Obesity during the COVID-19 Pandemic.
    Lim S; Shin SM; Nam GE; Jung CH; Koo BK
    J Obes Metab Syndr; 2020 Jun; 29(2):84-98. PubMed ID: 32544885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Important Management Considerations In Patients With Pituitary Disorders During The Time Of The Covid-19 Pandemic.
    Yuen KCJ; Blevins LS; Findling JW
    Endocr Pract; 2020 Aug; 26(8):915-922. PubMed ID: 33471683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Better COVID-19 Intensive Care Unit survival in females, independent of age, disease severity, comorbidities, and treatment.
    Meijs DAM; van Bussel BCT; Stessel B; Mehagnoul-Schipper J; Hana A; Scheeren CIE; Peters SAE; van Mook WNKA; van der Horst ICC; Marx G; Mesotten D; Ghossein-Doha C;
    Sci Rep; 2022 Jan; 12(1):734. PubMed ID: 35031644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repurposing existing drugs for COVID-19: an endocrinology perspective.
    Cadegiani FA
    BMC Endocr Disord; 2020 Sep; 20(1):149. PubMed ID: 32993622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Obesity on Clinical Outcomes in COVID-19 Patients.
    Habis Y; Alsilmi R; Alirbidi L; Safhi M; Alsallum F; Alharbi R; Samman A
    Cureus; 2023 Jan; 15(1):e33734. PubMed ID: 36793811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylactic anticoagulants for people hospitalised with COVID-19.
    Flumignan RL; Tinôco JDS; Pascoal PI; Areias LL; Cossi MS; Fernandes MI; Costa IK; Souza L; Matar CF; Tendal B; Trevisani VF; Atallah ÁN; Nakano LC
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013739. PubMed ID: 33502773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.